Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LLGL2 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
LLGL2 small interfering RNA (siRNA) is a synthetic double-stranded RNA molecule designed to silence the expression of the LLGL2 (Lethal giant larvae homolog 2) gene through the RNA interference (RNAi) pathway. LLGL2 is a cell polarity protein that plays a critical role in maintaining epithelial cell structure and asymmetric cell division. In research settings, particularly concerning epithelial ovarian cancer (EOC), LLGL2 siRNA is utilized to investigate the protein's function as a tumor suppressor. Studies have shown that silencing LLGL2 leads to increased cell migration and invasion by disrupting its interaction with ACTN1 (Alpha-actinin-1), which normally regulates cytoskeletal remodeling and actin filament bundling. While primarily used as a functional genomics tool in preclinical research, siRNAs targeting cell polarity factors represent an experimental category of RNA-based therapeutics.
- Other names
- LLGL2 siRNALLGL-2 siRNALLGL 2 siRNAsi-LLGL2si-LLGL-2si-LLGL 2Lethal giant larvae homolog 2 small interfering RNA
02
Targets
LLGL2 (Lethal giant larvae homolog 2)
Beyond the preview
Go deeper on LLGL2 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LLGL2 small interfering RNA.